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Abstract
Purpose—Growing evidence suggests an association between active cigarette smoking and 
increased breast cancer risk. However, the weak magnitude of association and conflicting results 
have yielded uncertainty and it is unknown whether associations differ by breast cancer subtype.
Methods—Using population-based case–control data from phases I and II of the Carolina Breast 
Cancer Study, we examined associations between self-reported measures of smoking and risk of 
Luminal and Basal-like breast cancers. We used logistic regression models to estimate case–
control odds ratios (OR) and 95 % confidence intervals (CI).
Results—Ever smoking (current and former) was associated with a weakly increased risk of 
Luminal breast cancer (OR 1.12, 95 % CI 0.92–1.36) and was not associated with risk of Basal-
like breast cancer (OR 0.96, 95 % CI 0.69–1.32). Similarly, smoking duration of more than 20 
years was associated with increased risk of Luminal (OR 1.51, 95 % CI 1.19–1.93), but not Basal-
like breast cancer (OR 0.90, 95 % CI 0.57–1.43). When stratified by race, elevated odds ratios 
between smoking and Luminal breast cancer risk were found among black women across multiple 
exposure measures (ever smoking, duration, and dose); conversely, among white women odds 
ratios were attenuated or null.
Conclusions—Results from our study demonstrate a positive association between smoking and 
Luminal breast cancer risk, particularly among black women and women with long smoking 
histories. Addressing breast cancer heterogeneity in studies of smoking and breast cancer risk may 
elucidate associations masked in prior studies.
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Introduction
In a 2014 report on the health consequences of cigarette smoking, the US Surgeon General 
concludes that there is insufficient evidence to suggest a causal relationship between active 
smoking and breast cancer risk [1]. Indeed, epidemiologic studies of smoking and breast 
cancer risk have yielded mixed results. Because many breast cancers are estrogen dependent 
[2], studies that report earlier menopause and lower circulating levels of estrogen among 
smokers support an “anti-estrogenic” effect of smoking and would suggest inverse 
associations [3]. However, few epidemiologic studies have supported this hypothesis [4, 5]. 
Epidemiologic studies have more commonly suggested a positive association [6–9], 
consistent with tissue culture and animal experiments showing that cigarette smoke 
components disrupt cell-cycle regulation, cause DNA damage, and are linked to malignant 
transformation [10–12].
Adding complexity to studies of smoking and breast cancer risk is the observation that breast 
cancer is a heterogeneous disease defined by distinct and reproducible gene expression 
profiles [13]. These gene expression profiles have identified breast tumor “intrinsic 
subtypes” that are prognostic and predictive of response to treatment [14]. In addition, these 
subtypes have different patterns of risk factor associations [15], consistent with the 
categorization of breast cancers into at least two etiologic types [16]. Growing evidence 
suggests a possible link between smoking and the Luminal, hormone receptor positive (HR
+) breast cancer types, ranging from a modest 5 % increased risk to more than doubled risk 
when comparing ever smokers with never smokers [6–9, 17–20]. Given that the associations 
between smoking and breast cancer may be subtype specific, and subtype prevalence varies 
by study, breast cancer heterogeneity may influence agreement between studies.
Using case–control data from phases I and II of the Carolina Breast Cancer Study, we 
describe associations between self-reported measures of smoking and risk of Luminal or 
Basal-like breast cancers. We also examine associations by race to determine whether 
smoking is linked to differential risk of either breast cancer subtype among black versus 
white women. By considering the heterogeneous nature of breast cancer, findings from this 
study may elucidate associations masked in prior investigations of smoking and breast 
cancer risk.
Methods
Study design
The Carolina Breast Cancer Study (CBCS) combines molecular biology and epidemiology 
to examine genetic and environmental risk factors for breast cancer [21]. Phases I and II of 
the population-based case–control study were conducted in 24 adjoining counties in central 
and eastern North Carolina from 1993–1996 and 1996–2001, respectively. The latter phase 
was included to increase sample size. Smoking exposures and study participant 
characteristics did not differ appreciably between the two phases.
Butler et al. Page 2
Cancer Causes Control. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Case selection
The present study includes women diagnosed with invasive breast cancer. CBCS cases were 
identified by a rapid case ascertainment system implemented through collaboration with the 
North Carolina Central Cancer Registry (NCCCR). To be eligible for inclusion as a case the 
patient must have been female and received a first diagnosis of invasive breast cancer 
between 1 May 1993 and 30 September 1995 (Phase I) or 1 May 1996 and 30 September 
2001 (Phase II). The patient also must have resided in the 24-county study region and been 
between the ages of 20 and 74 at the time of diagnosis.
To facilitate identification of differences in breast cancer etiology by race and age, cases 
were selected using a randomized recruitment strategy that oversampled black and young 
women. The patient’s treating physician was contacted to seek permission to invite the 
patient to participate in the study, yielding a case response rate of 76 %. In total, invasive 
cases included 787 black women and 1,016 white or non-black women.
Control selection
Population-based controls were selected using an incidence density sampling strategy and 
frequency-matched to cases by 5-year age group, race, and county of residence. Women 
aged 20–64 years old were identified through the North Carolina Division of Motor Vehicle 
records; those aged 65 years and older were identified through Medicare claims records. 
Women were invited to participate in the study by mail, yielding a control response rate of 
55 %. In total, controls matched to invasive cases included 718 black women and 846 white 
or non-black women; and controls matched to carcinoma in situ cases included 70 black 
women and 388 white or non-black women.
Exposure and outcome assessments
In accordance with regulations outlined by the Institutional Review Board at the University 
of North Carolina at Chapel Hill School of Medicine, cases and controls provided informed 
consent to participate in an in-person nurse-administered interview, which included 
anthropometric measurements and blood sample collection. Nurses used a standard 
questionnaire to obtain information on family history of cancer; menstrual and reproductive 
history; weight and body size recall during youth and early adulthood; occupational 
exposures; physical activity engagement; alcohol use; smoking history; exogenous hormone 
use; and socioeconomic status. Anthropometric measurements were taken in duplicate to 
obtain weight (lbs), height (inches), waist (cm), and hip circumference (cm).
Smoking exposure
Active smokers were defined as women who reported smoking 100 cigarettes or more 
during their lifetimes. Women were also asked to report age at smoking initiation and, where 
applicable, age at smoking cessation. On average, interviews were conducted 6 months 
following case ascertainment. Since a breast cancer diagnosis is likely to influence decisions 
concerning smoking cessation, we defined current smokers as women who self-reported 
smoking at the time of interview and women who reported smoking cessation at the same 
age of case/control selection. Former smokers were defined as women who quit at any age 
prior to the age at case/control selection. These data were used to derive smoking duration 
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(years), years since smoking cessation, and categories of smoking initiation relative to age at 
menarche and/or age at first full-term pregnancy. Women with a history of smoking were 
also asked to estimate the number of cigarette packs smoked per day.
Breast cancer outcome
Cases provided informed consent that allowed CBCS investigators to obtain medical 
records, pathology reports, and paraffin-embedded tumor blocks through coordination with 
the hospital where surgery was to be performed. For invasive cases, estrogen receptor (ER) 
positivity and progesterone receptor (PR) positivity were obtained from the patient’s medical 
records. Tumor blocks were sectioned and stained for three additional immunohistochemical 
(IHC) markers to define breast cancer molecular subtype; these markers include human 
epidermal growth factor receptor-2 (HER2); human epidermal growth factor receptor-1 
(HER1); and cytokeratin 5/6 (CK5/6). Assay procedures and cut points for positivity have 
been described, previously [22, 23]. IHC staining was performed at the IHC Core 
Laboratory, University of North Carolina. Luminal breast cancers were defined as (ER+ 
and/or PR+, regardless of HER2 status), and Basal-like tumors were defined as (ER−, PR−, 
HER2−, HER1+ and/or CK5/6+).
Other measures
Race was based on self-report and the majority of women self-identified as black or white. 
Less than 2 % of women self-identified as Native American, Asian, mixed, or other race (n = 
53). We described study participants as black or white and combined the small number of 
women who did not self-identify as black or white with analyses of white study participants; 
notably, excluding non-black and non-white women from our analyses did not result in 
substantially different race-specific associations between smoking and breast cancer risk. 
Age was self-reported at time of case/control selection. Women aged <50 were defined as 
postmenopausal if they experienced natural menopause, bilateral oophorectomy, or had 
irradiation to the ovaries. For women aged ≥50, postmenopausal status was based on the 
cessation of menstruation by any means. All other women were assigned as being 
premenopausal. Women were considered to have a first-degree family history of breast 
cancer if their biological mother or a full female sibling had been diagnosed with breast 
cancer. Alcohol use was defined as recent, former, or never, relative to age at case/control 
selection. Oral contraceptive use was defined by four categories of usage: never, <5, 5–10, or 
>10 years. Women were defined as parous if they reported ever having a live birth or having 
a pregnancy that lasted 7 months or more. Breastfeeding behavior was defined using three 
categories, according to the age when the study participant first experienced breastfeeding: 
never, ≤24, ≥25. Age at menarche was defined as the age the woman experienced onset of a 
regular menstrual cycle. Body mass index (BMI = body weight (kg)/height (m)2) was 
categorized according to cut points outlined by the National Heart, Lung, and Blood Institute 
(NHLBI) (<25 normal or underweight, 25–29 overweight, ≥30 obese). Hormone 
replacement therapy use was defined as ever or never. And age at first birth was 
characterized as <25 or ≥25 years.
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Data analysis
We examined the relationship between smoking exposure and risk of invasive breast cancer, 
according to race and breast cancer molecular subtype. We used unconditional logistic 
regression with polytomous outcomes and 95 % confidence intervals to estimate the 
association between smoking exposure and breast cancer risk. To evaluate heterogeneity 
across subtype-specific odds ratios, we reported p values for likelihood ratio tests that 
compared case-only models with or without each smoking measure as an explanatory value 
and used a statistical significance level of alpha = 0.05. All odds ratios were adjusted for 
randomized recruitment probabilities using an offset term. Potential confounders were 
selected and adjusted for based upon literature review and directed acyclic graph analysis. 
These variables included age, family history, alcohol use, menopausal status, hormone 
replacement therapy use, oral contraceptive use, parity, age at first birth, age at first 
breastfeeding, age at menarche, and BMI. All analyses were conducted using SAS 9.4 (SAS 
Institute Inc, Cary, NC).
Results
Table 1 describes characteristics of breast cancer cases and controls in the Carolina Breast 
Cancer Study. Compared to controls, cases were more likely to have a first-degree family 
history of breast cancer and were also more likely to be nulliparous. Fewer cases were 
postmenopausal compared to controls and a fewer cases had a body mass index of 25 or 
greater. Cases and controls did not differ appreciably with respect to alcohol use, oral 
contraceptive use, age at menarche, or age at first breastfeeding (among parous women).
Smoking measures, their associated case–control odds ratios, and 95 % confidence intervals 
are presented in Table 2. Overall, history of ever smoking was associated with a weakly 
increased risk of breast cancer (OR 1.07, 95 % CI 0.92–1.25). Smoking status, defined as 
current, former, or never, and smoking dose, defined as the number of cigarette packs 
smoked per day, also showed weakly positive associations with overall breast cancer risk. 
The strongest association was observed for smokers with duration of smoking greater than 
20 years compared to non-smokers (OR 1.33, 95 % CI 1.09–1.61). The relationship between 
long smoking duration (>20 years) and breast cancer risk persisted when limiting the 
analysis to either current (OR 1.22, 95 % CI 0.97–1.53) or former smokers (OR 1.54, 95 % 
CI 1.15–2.07). Current smokers were more likely than former smokers to have smoking 
histories that totaled 20 years or greater (67 vs. 30 %). In addition, former smokers who quit 
5–10 years prior to case/control selection had increased risk of breast cancer (OR 1.39, 95 % 
CI 1.01–1.93). Smoking initiation following adolescence (>20 years old) was associated 
with a small increase in risk (OR 1.07, 95 % CI 0.89–1.28). Further, smoking initiation 
relative to menarche and first full-term pregnancy were not associated with increased risk of 
breast cancer. Specifically, we did not observe an appreciable association between smoking 
and breast cancer risk for: (1) smoking initiation prior to menarche; (2) smoking initiation 
after menarche and ≥11 years before first full-term pregnancy; or (3) smoking initiation after 
menarche and <11 years before first full-term pregnancy.
Table 3 presents smoking measures and case–control odds ratios for Luminal and Basal-like 
subtypes. Compared with never smokers, ever smokers had a slight increased risk of 
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Luminal type breast cancer (OR 1.12, 95 % CI 0.92–1.36) and a weakly decreased odds ratio 
for Basal-like breast cancer (OR 0.96, 95 % CI 0.69–1.32). Smoking more than 20 years 
(OR 1.51, 95 % CI 1.19–1.93) was associated with increased risk of Luminal breast cancer 
subtype. For smoking intensity of one or more cigarette packs per day, we observed an 
inverse association with the Basal-like breast cancer type (OR 0.47, 95 % CI 0.25–0.89). In 
general, strata of time since smoking cessation did not show a consistent pattern of 
association with risk of Luminal or Basal-like breast cancer risk. Similar to results for 
overall breast cancer risk, smoking initiation following the adolescent period (>20 years of 
age) was associated with a slight increased risk of Luminal disease (OR 1.18, 95 % CI 0.88–
1.57). Our tests of heterogeneity demonstrated statistically different odds ratios for the 
Luminal and Basal-like subtypes for smoking dose (p = 0.02) and duration (p = 0.00).
In Table 4, we extended the subtype-specific analyses to explore differences by race. Among 
black women, the magnitudes of the case–control odds ratios were substantially greater than 
those observed for white women. Current smoking (OR 1.53, 95 % CI 1.04–2.26) and long 
smoking duration (OR 2.06, 95 % CI 1.38–3.06) were associated with increased risks of 
Luminal type breast cancer among black women; however, current smoking (OR 0.91, 95 % 
CI 0.65–1.26) and long smoking duration (OR 1.31, 95 % CI 0.96–1.79) had weaker 
associations with Luminal breast cancer risk among white women. For the Basal-like breast 
cancer type, former smoking was associated with increased risk among black women (OR 
1.71, 95 % CI 1.02–2.86) and smoking dose was associated with inverse risk among white 
women (OR 0.38, 95 % CI 0.16–0.90). Our tests of heterogeneity demonstrated statistically 
different odds ratios for the Luminal and Basal-like subtypes for smoking status (p = 0.02) 
and duration (p = 0.06) among black women and smoking dose (p = 0.10) among white 
women.
Discussion
In this paper, we describe associations between active smoking and breast cancer risk in the 
Carolina Breast Cancer Study [21]. Using a case–control study design, we report a weakly 
increased risk of breast cancer for women who were ever smokers (current and former) and a 
more pronounced increase in risk among women who smoked more than 20 years. This 
finding differed by race, where long smoking duration (>20 years) was associated with 
higher risk of breast cancer for black women, but not white women. Our subtype-specific 
analyses demonstrated that both current smoking and long smoking duration were associated 
with increased risk of Luminal breast cancers, but not Basal-like breast cancers—where 
subtypes were defined by the joint expression of the estrogen receptor, progesterone 
receptor, and three other immunohistochemical (IHC) markers used to determine breast 
cancer intrinsic subtype [24]. Subtype specificity of smoking-associated risk persisted when 
examining tumors by hormone receptor and triple-negative status, as current and long-term 
smoking were associated with HR-positive (HR+) breast tumors, but not HR-negative (HR−) 
or triple-negative breast tumors. By examining breast cancer heterogeneity, results from this 
study may elucidate associations masked in prior investigations of smoking and breast 
cancer risk.
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At present, there is no consensus on whether smoking is associated with breast cancer risk. 
We observed a weak risk increase (~7 %) among women who were classified as “ever 
smokers” and a slightly higher risk increase (~12 %) when examining the association 
between “ever smokers” and the Luminal breast cancer type. Our observed associations are 
weaker than those reported by Kawai et al., who demonstrated a 30 % increased risk of any 
breast cancer and a 40 % increased risk of ER + breast cancer among “ever smokers” in a 
population-based case–control study of women in the Seattle Puget-Sound metropolitan area 
[18]. Notably, none of the smoking measures considered by Kawai et al. were associated 
with the Basal-like or ER− breast cancer types. However, in our study we observed inverse 
associations between smoking dose and Basal-like breast cancer risk, with evidence for 
statistically significant heterogeneity of the subtype-specific ORs for dose and duration. 
These observations suggest that active smoking may be both quantitatively and qualitatively 
associated with increased risk of Luminal disease and inverse risk of Basal-like breast 
tumors. Nevertheless, a number of previous studies have reported positive associations 
between smoking and ER− breast tumors [19, 25–27], while others have reported null 
associations between smoking and either subtype (i.e., ER+ and ER−) [28, 29] or inverse 
associations between smoking and the ER+ subtype [30]. It is important to note that these 
studies vary in population, study design, and the specific smoking measures used for their 
analyses.
The heterogeneous nature of breast cancer is well established with the identification of 
distinct and reproducible “intrinsic subtypes” that predict prognosis and response to 
treatment; however, less is known concerning the utility of these subtypes in studies of 
etiology [14, 16]. Breast cancer incidence trends have been used to suggest the existence of 
two main etiologic types—the Luminal and Basal-like types—based on estrogen receptor 
expression and average age at onset. Basal-like breast cancers are ER− and have an early 
average age at onset relative to Luminal breast cancers, which are ER+ and have a later 
average age at onset [16, 31, 32]. These observations, together with results from previous 
studies of breast cancer etiology, support arguments that breast cancers of Luminal epithelial 
and basal/myoepithelial origins represent two distinct diseases with distinct risk factor 
profiles [15]. Thus, if the relationship between smoking and breast cancer risk is specific to 
the Luminal breast cancer type and has no association with the Basal-like breast cancer type, 
characterizing breast cancer as a homogenous disease in studies of etiology results in 
outcome misclassification and may bias effect measure estimates, as evidenced by the 
attenuated case–control odds ratios observed in our study [33].
The empirical induction period between smoking initiation and breast cancer diagnosis is 
thought to be as much as 40 years in general populations of women [34, 35]. Results from 
our study are consistent with a long induction period, as women who smoked 20 years or 
longer had a more than 50 % increased risk of developing Luminal breast cancers. Further, 
among former smokers smoking cessation within 5–10 years of case/control selection was 
associated with increased Luminal breast cancer risk, whereas quitting within 5 or ≥11 years 
was not associated with risk. Previous studies have also demonstrated an association 
between smoking cessation 5–10 years prior to interview date and increased risk of ER+ or 
any breast cancer [6, 18]. These results suggest that the anti-estrogenic properties of 
cigarette smoke could suppress breast cancer development during periods of active smoking, 
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which may otherwise have developed via estrogenic pathways. Future studies of smoking 
and subtype-specific breast cancer risk would benefit by critically evaluating smoking 
exposures among pre- and postmenopausal women, as levels of endogenous estrogens may 
interact with anti-estrogenic properties of cigarette smoke. Indeed, a number of studies have 
demonstrated differential effects of smoking among pre- and postmenopausal women for 
overall breast cancer risk, thereby suggesting biological interactions between smoking and 
endogenous estrogens [8, 9].
In general, both black and white women with smoking histories had increased risk of 
Luminal type breast cancers in CBCS. However, the strength of the associations between 
current smoking or long smoking duration and breast cancer risk was greater among black 
women; there was no pattern of elevated odds ratios among white women. We interpret these 
results cautiously as prior studies have reported positive associations between smoking and 
breast cancer risk in populations of black and white women [6, 9]. However, the differing 
magnitudes of the effect estimates observed in our study may reflect differences in 
unmeasured co-exposures or genetic variants. Several studies have investigated racial 
differences for smoking interaction with polymorphisms of the cytochrome P-450 enzymes 
and DNA repair genes, which act to neutralize the effects of DNA damage from carcinogens 
in cigarette smoke. These studies identified variants of CYP1A1 and several nucleotide 
excision repair genes that were associated with higher risks of breast cancer among black 
smokers when compared with white smokers [36, 37]. There is also evidence to suggest that 
smoking may be associated with differential risks of other carcinomas, according to race or 
ethnicity. In a study of smoking and lung cancer risk, African American and Native 
American smokers were more likely to develop lung cancer when compared with Japanese 
Americans, Latino Americans, and White Americans [38]. Similarly, researchers have 
observed higher associations between smoking and head and neck cancers among African 
Americans when compared with White Americans, after controlling for other traditional risk 
factors [39]. Thus, in addition to subtype-specific investigations, future studies of smoking 
and breast cancer risk may benefit by examining associations by race.
The results presented in this paper should be interpreted in consideration of our study’s 
limitations and strengths. Notably, case–control study designs may be susceptible to recall 
bias, with cases showing differential accuracy in recalling smoking histories. However, the 
use of self-reported smoking measures is shown to be a reliable method for active smoking 
assessment in the general US population [40]. In addition, urinary cotinine concentrations 
have been used to demonstrate the validity of self-reported smoking status (i.e., current, 
former, or never) [41]. The 55 % response rate among controls may generate concerns of 
selections bias since it is believed that non-smokers may be more likely to participate as 
controls in epidemiology studies [42]. However, 20 % of CBCS controls reported that they 
were current smokers, which is comparable to the 1995 estimate of 22 % for smoking 
prevalence among women in North Carolina [43]. Finally, we note that our race, subtype-
specific, and other stratified analyses are limited by small sample size. Although several 
studies have reported associations between smoking before first pregnancy and breast cancer 
risk, our small sample sizes may have limited our ability to observe overall and subtype-
specific associations.
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Our investigation of smoking and breast cancer risk had a number of strengths. To our 
knowledge, this is the first study to examine the association between smoking and etiologic 
subtypes of breast cancer—the Luminal and Basal-like breast cancer types—by staining for 
proteins specific to Basal-like breast cancers [24]. Prior studies have examined smoking and 
subtype-specific breast cancer risk in relation to IHC staining of one or more of three 
clinical markers, which include the estrogen receptor, progesterone receptor and human 
epidermal growth factor receptor-2 (HER2). The additional IHC staining for human 
epidermal growth factor receptor-1 (HER1) and cytokeratin 5/6 (CK5/6) allowed us greater 
classification accuracy in identifying Basal-like breast cancers. Further, the CBCS 
oversampled young and black women, which allowed us to examine potential race 
differences for smoking and type specific breast cancer risk.
In conclusion, results from our study demonstrate associations between smoking and 
Luminal breast cancer risk, particularly among black women and women with long smoking 
histories. In addition, current smokers and former smokers with long smoking histories may 
be at higher risk of developing Luminal breast cancer. By examining active smoking 
exposure in relation to etiologic types of breast cancer, future investigations may clarify the 
unsettled question of whether smoking is associated with increased breast cancer risk.
Acknowledgments
This work was supported by the North Carolina University Cancer Research Fund, a Grant from the Komen 
Foundation, and a National Cancer Institute Specialized Program of Research Excellence Grant, P50-CA058223.
References
1. Alberg AJ, Shopland DR, Cummings KM. The 2014 Surgeon General’s report: commemorating the 
50th anniversary of the 1964 report of the advisory committee to the US Surgeon General and 
updating the evidence on the health consequences of cigarette smoking. Am J Epidemiol. 2014; 
179(4):403–412. DOI: 10.1093/aje/kwt335 [PubMed: 24436362] 
2. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA. US incidence of 
breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 
2014; doi: 10.1093/jnci/dju055
3. Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J 
Obstet Gynecol. 1990; 162(2):502–514. DOI: 10.1016/0002-9378(90)90420-C [PubMed: 2178432] 
4. Palmer JR, Viscidi E, Troester MA, Hong CC, Schedin P, Bethea TN, Bandera EV, Borges V, 
McKinnon C, Haiman CA, Lunetta K, Kolonel LN, Rosenberg L, Olshan AF, Ambrosone CB. 
Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER 
Consortium. J Natl Cancer Inst. 2014; doi: 10.1093/jnci/dju237
5. Terry PD, Rohan TE. Cigarette smoking and the risk of breast cancer in women a review of the 
literature. Cancer Epidemiol Biomark Prev. 2002; 11(10):953–971.
6. Gaudet MM, Gapstur SM, Sun J, Diver WR, Hannan LM, Thun MJ. Active smoking and breast 
cancer risk: original cohort data and meta-analysis. J Natl Cancer Inst. 2013; 105(8):515–525. DOI: 
10.1093/jnci/djt023 [PubMed: 23449445] 
7. Nyante S, Gierach G, Dallal C, Freedman N, Park Y, Danforth K, Hollenbeck A, Brinton L. 
Cigarette smoking and post-menopausal breast cancer risk in a prospective cohort. Br J Cancer. 
2014; 110(9):2339–2347. [PubMed: 24642621] 
8. Xue F, Willett WC, Rosner BA, Hankinson SE, Michels KB. Cigarette smoking and the incidence of 
breast cancer. Arch Intern Med. 2011; 171(2):125–133. DOI: 10.1001/archinternmed.2010.503 
[PubMed: 21263102] 
Butler et al. Page 9
Cancer Causes Control. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
9. Rosenberg L, Boggs DA, Bethea TN, Wise LA, Adams-Campbell LL, Palmer JR. A prospective 
study of smoking and breast cancer risk among African-American women. Cancer Causes Control 
CCC. 2013; 24(12):2207–2215. DOI: 10.1007/s10552-013-0298-6 [PubMed: 24085586] 
10. Nishioka T, Kim HS, Luo LY, Huang Y, Guo J, Chen CY. Sensitization of epithelial growth factor 
receptors by nicotine exposure to promote breast cancer cell growth. Breast Cancer Res. 2011; 
13(6):R113.doi: 10.1186/bcr3055 [PubMed: 22085699] 
11. Chen CS, Lee CH, Hsieh CD, Ho CT, Pan MH, Huang CS, Tu SH, Wang YJ, Chen LC, Chang YJ, 
Wei PL, Yang YY, Wu CH, Ho YS. Nicotine-induced human breast cancer cell proliferation 
attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins. 
Breast Cancer Res Treat. 2011; 125(1):73–87. DOI: 10.1007/s10549-010-0821-3 [PubMed: 
20229177] 
12. Melendez-Colon VJ, Luch A, Seidel A, Baird WM. Cancer initiation by polycyclic aromatic 
hydrocarbons results from formation of stable DNA adducts rather than apurinic sites. 
Carcinogenesis. 1999; 20(10):1885–1891. [PubMed: 10506100] 
13. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, 
Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D. 
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl 
Acad Sci USA. 2003; 100(14):8418–8423. DOI: 10.1073/pnas.0932692100 [PubMed: 12829800] 
14. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu 
Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis 
MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. 
J Clin Oncol. 2009; 27(8):1160–1167. DOI: 10.1200/JCO.2008.18.1370 [PubMed: 19204204] 
15. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, 
Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM. Epidemiology 
of basal-like breast cancer. Breast Cancer Res Treat. 2008; 109(1):123–139. DOI: 10.1007/
s10549-007-9632-6 [PubMed: 17578664] 
16. Anderson WF, Matsuno R. Breast cancer heterogeneity: A mixture of at least two main types? J 
Natl Cancer Inst. 2006; 98(14):948–951. DOI: 10.1093/jnci/djj295 [PubMed: 16849671] 
17. Kabat GC, Kim M, Phipps AI, Li CI, Messina CR, Wactawski-Wende J, Kuller L, Simon MS, 
Yasmeen S, Wassertheil-Smoller S, Rohan TE. Smoking and alcohol consumption in relation to 
risk of triple-negative breast cancer in a cohort of post-menopausal women. Cancer Causes Control 
CCC. 2011; 22(5):775–783. DOI: 10.1007/s10552-011-9750-7 [PubMed: 21360045] 
18. Kawai M, Malone KE, Tang MT, Li CI. Active smoking and the risk of estrogen receptor-positive 
and triple-negative breast cancer among women ages 20 to 44 years. Cancer. 2014; 120(7):1026–
1034. DOI: 10.1002/cncr.28402 [PubMed: 24515648] 
19. Morabia A, Bernstein M, Ruiz J, Heritier S, Diebold Berger S, Borisch B. Relation of smoking to 
breast cancer by estrogen receptor status. Int J Cancer. 1998; 75(3):339–342. [PubMed: 9455790] 
20. Dossus L, Boutron-Ruault MC, Kaaks R, Gram IT, Vilier A, Fervers B, Manjer J, Tjonneland A, 
Olsen A, Overvad K. Active and passive cigarette smoking and breast cancer risk: results from the 
EPIC cohort. Int J Cancer. 2014; 134(8):1871–1888. [PubMed: 24590452] 
21. Newman B, Moorman PG, Millikan R, Qaqish BF, Geradts J, Aldrich TE, Liu ET. The Carolina 
Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast 
Cancer Res Treat. 1995; 35(1):51–60. [PubMed: 7612904] 
22. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse 
CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, 
Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. 
JAMA. 2006; 295(21):2492–2502. DOI: 10.1001/jama.295.21.2492 [PubMed: 16757721] 
23. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan 
RC. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol. 2007; 
38(2):197–204. DOI: 10.1016/j.humpath.2006.08.017 [PubMed: 17234468] 
24. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, 
Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. 
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast 
carcinoma. Clin Cancer Res. 2004; 10(16):5367–5374. DOI: 10.1158/1078-0432.CCR-04-0220 
[PubMed: 15328174] 
Butler et al. Page 10
Cancer Causes Control. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
25. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L. Smoking associated with 
hormone receptor negative breast cancer. Int J Cancer. 2001; 91(4):580–584. [PubMed: 11251985] 
26. Nishino Y, Minami Y, Kawai M, Fukamachi K, Sato I, Ohuchi N, Kakugawa Y. Cigarette smoking 
and breast cancer risk in relation to joint estrogen and progesterone receptor status: a case–control 
study in Japan. SpringerPlus. 2014; 3(1):65. [PubMed: 24516791] 
27. Cooper JA, Rohan TE, Cant EL, Horsfall DJ, Tilley WD. Risk factors for breast cancer by 
oestrogen receptor status: a population-based case–control study. Br J Cancer. 1989; 59(1):119–
125. [PubMed: 2757918] 
28. Turkoz FP, Solak M, Petekkaya I, Keskin O, Kertmen N, Sarici F, Arik Z, Babacan T, Ozisik Y, 
Altundag K. Association between common risk factors and molecular subtypes in breast cancer 
patients. Breast. 2013; 22(3):344–350. DOI: 10.1016/j.breast.2012.08.005 [PubMed: 22981738] 
29. Rusiecki JA, Holford TR, Zahm SH, Zheng T. Breast cancer risk factors according to joint estrogen 
receptor and progesterone receptor status. Cancer Detect Prev. 2005; 29(5):419–426. DOI: 
10.1016/j.cdp.2005.07.004 [PubMed: 16185815] 
30. Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW. The epidemiology of 
triple-negative breast cancer, including race. Cancer Causes Control CCC. 2009; 20(7):1071–1082. 
DOI: 10.1007/s10552-009-9331-1 [PubMed: 19343511] 
31. Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How many etiological subtypes of 
breast cancer: Two, three, four, or more? J Natl Cancer Inst. 2014; doi: 10.1093/jnci/dju165
32. Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM. Shifting breast cancer trends in the United 
States. J Clin Oncol. 2007; 25(25):3923–3929. DOI: 10.1200/JCO.2007.11.6079 [PubMed: 
17679726] 
33. Jurek AM, Greenland S, Maldonado G. How far from non-differential does exposure or disease 
misclassification have to be to bias measures of association away from the null? Int J Epidemiol. 
2008; 37(2):382–385. DOI: 10.1093/ije/dym291 [PubMed: 18184671] 
34. Cui Y, Miller AB, Rohan TE. Cigarette smoking and breast cancer risk: update of a prospective 
cohort study. Breast Cancer Res Treat. 2006; 100(3):293–299. DOI: 10.1007/s10549-006-9255-3 
[PubMed: 16773435] 
35. Terry PD, Miller AB, Rohan TE. Cigarette smoking and breast cancer risk: a long latency period? 
Int J Cancer. 2002; 100(6):723–728. DOI: 10.1002/ijc.10536 [PubMed: 12209614] 
36. Li Y, Millikan RC, Bell DA, Cui L, Tse CK, Newman B, Conway K. Cigarette smoking, 
cytochrome P4501A1 polymorphisms, and breast cancer among African-American and white 
women. Breast Cancer Res. 2004; 6(4):R460–R473. DOI: 10.1186/bcr814 [PubMed: 15217514] 
37. Mechanic LE, Millikan RC, Player J, de Cotret AR, Winkel S, Worley K, Heard K, Heard K, Tse 
CK, Keku T. Polymorphisms in nucleotide excision repair genes, smoking and breast cancer in 
African Americans and whites: a population-based case–control study. Carcinogenesis. 2006; 
27(7):1377–1385. DOI: 10.1093/carcin/bgi330 [PubMed: 16399771] 
38. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, Le Marchand L. 
Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med. 2006; 
354(4):333–342. DOI: 10.1056/NEJMoa033250 [PubMed: 16436765] 
39. Stingone JA, Funkhouser WK, Weissler MC, Bell ME, Olshan AF. Racial differences in the 
relationship between tobacco, alcohol, and squamous cell carcinoma of the head and neck. Cancer 
Causes Control CCC. 2013; 24(4):649–664. DOI: 10.1007/s10552-012-9999-5 [PubMed: 
22674225] 
40. Soulakova JN, Hartman AM, Liu B, Willis GB, Augustine S. Reliability of adult self-reported 
smoking history: data from the tobacco use supplement to the current population survey 2002–
2003 cohort. Nicotine Tob Res. 2012; 14(8):952–960. DOI: 10.1093/ntr/ntr313 [PubMed: 
22318688] 
41. Studts JL, Ghate SR, Gill JL, Studts CR, Barnes CN, LaJoie AS, Andrykowski MA, LaRocca RV. 
Validity of self-reported smoking status among participants in a lung cancer screening trial. Cancer 
Epidemiol Biomarkers Prev. 2006; 15(10):1825–1828. DOI: 10.1158/1055-9965.EPI-06-0393 
[PubMed: 17035388] 
42. Palmer JR, Rosenberg L. Cigarette smoking and the risk of breast cancer. Epidemiol Rev. 1993; 
15(1):145–156. [PubMed: 8405197] 
Butler et al. Page 11
Cancer Causes Control. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
43. Centers for Disease C, Prevention. State-specific prevalence of cigarette smoking—United States, 
1995. MMWR Morb Mortal Wkly Rep. 1996; 45(44):962–966. [PubMed: 8965794] 
Butler et al. Page 12
Cancer Causes Control. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Butler et al. Page 13
Ta
bl
e 
1
CB
CS
 I 
an
d 
II
C
ha
ra
ct
er
ist
ic
s
C
as
es
C
on
tr
o
ls
Χ2
n
 =
 (1
80
8)
n
 =
 (1
56
4)
p 
va
lu
e
n
%
n
%
Ra
ce
B
la
ck
78
8
43
.6
71
8
45
.9
0.
18
W
hi
te
1,
02
0
56
.4
84
6
54
.1
A
ge
<
 5
0
97
6
54
.0
78
7
50
.3
0.
03
≥5
0
83
2
46
.0
77
7
49
.7
Po
stm
en
op
au
se
Ye
s
93
5
51
.7
84
6
54
.1
0.
17
N
o
87
3
48
.2
71
8
45
.9
M
iss
in
g
0
0
Fi
rs
t-d
eg
re
e f
am
ily
 h
ist
or
y 
of
 b
re
as
t c
an
ce
r
Ye
s
29
2
16
.7
18
3
12
.1
0.
00
N
o
1,
46
1
83
.3
13
28
87
.9
M
iss
in
g
55
53
A
lc
oh
ol
 u
se
R
ec
en
t
1,
00
4
55
.6
86
3
55
.2
0.
70
Fo
rm
er
23
8
13
.2
19
4
12
.4
N
ev
er
56
5
31
.3
50
6
32
.4
M
iss
in
g
1
1
Or
al 
co
nt
ra
ce
pt
iv
e 
u
se
 (y
ear
s)
>
 1
0
22
8
12
.7
16
9
10
.9
0.
14
5–
10
41
1
22
.8
32
3
20
.8
<
 5
53
8
29
.9
48
9
31
.5
N
ev
er
62
5
34
.7
57
2
36
.8
M
iss
in
g
6
11
Pa
rit
y
Cancer Causes Control. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Butler et al. Page 14
C
ha
ra
ct
er
ist
ic
s
C
as
es
C
on
tr
o
ls
Χ2
n
 =
 (1
80
8)
n
 =
 (1
56
4)
p 
va
lu
e
n
%
n
%
≥3
65
9
36
.4
61
4
39
.3
0.
01
2
55
8
30
.9
49
5
31
.6
1
31
6
17
.5
28
1
18
.0
0
27
5
15
.2
17
4
11
.1
A
ge
 at
 fi
rs
t b
irt
h
≥2
5
47
8
26
.4
40
1
25
.6
0.
00
<
 2
5
1,
05
5
58
.4
98
9
63
.2
N
ev
er
27
5
15
.2
17
4
11
.1
A
ge
 at
 fi
rs
t b
re
as
tfe
ed
in
ga
≥2
5
29
0
19
.0
27
2
19
.6
0.
25
<
 2
5
34
1
22
.3
34
1
24
.6
N
ev
er
89
9
58
.8
77
6
55
.9
M
iss
in
g
3
1
A
ge
 at
 m
en
ar
ch
e
<
 1
2
1,
40
1
77
.5
1,
25
0
79
.9
0.
09
≥1
2
40
7
22
.5
31
4
20
.1
Bo
dy
 m
as
s i
nd
ex
 (k
g/m
2 )
≥3
0
62
6
35
.4
59
0
38
.6
0.
01
25
–2
9
51
5
29
.1
47
2
30
.9
<
 2
5
62
7
35
.5
46
6
30
.5
M
iss
in
g
40
36
Ch
ar
ac
te
ris
tic
s a
m
on
g 
br
ea
st 
ca
nc
er
 c
as
es
 a
nd
 c
on
tro
ls
a A
m
on
g 
pa
ro
us
 w
o
m
en
Cancer Causes Control. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Butler et al. Page 15
Ta
bl
e 
2
CB
CS
 I 
an
d 
II
C
ha
ra
ct
er
ist
ic
s
C
as
es
C
on
tr
o
ls
O
R
95
 %
 C
I
n
 
=
 (1
80
8)
n
 
=
 (1
56
4)
n
%
n
%
Sm
ok
in
g 
hi
sto
ry
N
ev
er
94
2
52
.1
84
0
53
.7
1.
00
Ev
er
86
6
47
.9
72
4
46
.3
1.
07
0.
92
1.
25
M
iss
in
g
0
0
Sm
ok
in
g 
sta
tu
s
N
ev
er
94
2
52
.1
84
0
53
.7
1.
00
Fo
rm
er
46
8
25
.9
39
8
25
.4
1.
11
0.
93
1.
33
Cu
rre
nt
39
8
22
.0
32
6
20
.8
1.
02
0.
84
1.
24
M
iss
in
g
0
0
Sm
ok
in
g 
do
se
 (p
ack
s p
er 
da
y)
N
ev
er
94
2
52
.2
84
0
53
.8
1.
00
<
 1
/2
29
1
16
.1
26
5
16
.9
1.
06
0.
86
1.
30
1/
2–
1
32
1
17
.8
24
4
15
.6
1.
12
0.
91
1.
38
>
 1
24
9
13
.8
21
2
13
.6
1.
03
0.
82
1.
29
M
iss
in
g
5
3
D
ur
at
io
n 
(ye
ars
)
N
ev
er
94
2
52
.2
84
0
53
.8
1.
00
≤1
0
23
5
13
.0
21
9
14
.0
0.
86
0.
69
1.
08
11
–2
0
20
6
11
.4
18
6
11
.9
0.
95
0.
75
1.
21
>
 2
0
42
0
23
.3
31
5
20
.2
1.
33
1.
09
1.
61
M
iss
in
g
5
4
D
ur
at
io
n 
am
on
g 
cu
rre
nt
 (y
ear
s)
N
ev
er
94
2
70
.4
0
84
0
72
.1
6
1.
00
≤1
0
48
3.
59
36
3.
09
0.
75
0.
46
1.
23
11
–2
0
82
6.
13
80
6.
87
0.
69
0.
48
0.
99
>
 2
0
26
6
19
.8
8
20
8
17
.8
7
1.
22
0.
97
1.
53
Cancer Causes Control. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Butler et al. Page 16
C
ha
ra
ct
er
ist
ic
s
C
as
es
C
on
tr
o
ls
O
R
95
 %
 C
I
n
 
=
 (1
80
8)
n
 
=
 (1
56
4)
n
%
n
%
M
iss
in
g
2
2
D
ur
at
io
n 
am
on
g 
fo
rm
er
 (y
ear
s)
N
ev
er
94
2
66
.9
5
84
0
67
.9
6
1.
00
≤1
0
18
7
13
.2
9
18
3
14
.8
1
0.
89
0.
70
1.
14
11
–2
0
12
4
8.
81
10
6
8.
58
1.
15
0.
85
1.
54
>
 2
0
15
4
10
.9
5
10
7
8.
66
1.
54
1.
15
2.
07
M
iss
in
g
3
2
Ye
ar
s 
sin
ce
 q
ui
tti
ng
 (f
orm
er)
N
ev
er
94
2
67
.1
4
84
0
67
.9
1
1.
00
<
 5
82
5.
84
66
5.
34
1.
02
0.
71
1.
48
5–
10
12
0
8.
55
78
6.
31
1.
39
1.
01
1.
93
11
–2
0
13
6
9.
69
12
6
10
.1
9
1.
04
0.
79
1.
37
>
 2
0
12
3
8.
77
12
7
10
.2
7
1.
01
0.
76
1.
35
M
iss
in
g
7
1
A
ge
 at
 in
iti
at
io
n 
(ye
ars
)
N
ev
er
94
2
52
.1
0
84
0
53
.7
1
1.
00
≤1
5
13
7
7.
58
11
2
7.
16
0.
89
0.
66
1.
19
16
–2
0
47
7
26
.3
8
41
0
26
.2
1
1.
07
0.
89
1.
28
>
 2
0
25
2
13
.9
4
20
2
12
.9
2
1.
19
0.
95
1.
49
M
iss
in
g
In
iti
at
io
n 
of
 sm
ok
in
g 
re
la
tiv
e 
to
 m
en
ar
ch
e &
 fi
rs
t f
ul
l-t
er
m
 p
re
gn
an
cy
N
ev
er
80
1
52
.2
5
73
5
52
.8
8
1.
00
≤M
en
ar
ch
e
48
3.
13
43
3.
09
0.
82
0.
51
1.
31
A
fte
r m
en
ar
ch
e,
 1
1+
 y
ea
rs
 b
ef
or
e 
FF
TP
80
5.
22
63
4.
53
1.
03
0.
70
1.
52
A
fte
r m
en
ar
ch
e,
 <
11
 y
ea
rs
 b
ef
or
e 
FF
TP
60
4
39
.4
0
54
9
39
.5
0
1.
02
0.
86
1.
21
O
dd
s r
at
io
s f
or
 sm
ok
in
g 
an
d 
br
ea
st 
ca
nc
er
 ri
sk
O
Rs
 a
dju
ste
d f
or 
ag
e, 
rac
e, 
fam
ily
 h
ist
or
y,
 
al
co
ho
l u
se
, m
en
op
au
sa
l s
ta
tu
s, 
or
al
 c
on
tra
ce
pt
iv
e 
u
se
, 
pa
rit
y,
 
ag
e 
at
 fi
rs
t b
irt
h,
 a
ge
 a
t f
irs
t b
re
as
tfe
ed
in
g,
 a
ge
 a
t m
en
ar
ch
e,
 b
od
y 
m
as
s i
nd
ex
, 
an
d 
of
fs
et
s
Cancer Causes Control. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Butler et al. Page 17
Ta
bl
e 
3
CB
CS
 I 
an
d 
II
C
ha
ra
ct
er
ist
ic
s
C
on
tr
o
ls
Lu
m
in
al
Ba
sa
l-l
ik
e
LR
T
C
on
tr
o
ls
C
as
es
O
R
95
 %
 C
I
C
as
es
O
R
95
 %
 C
I
p 
v
a
lu
e
n
%
n
%
n
%
Sm
ok
in
g 
hi
sto
ry
N
ev
er
84
0
53
.7
36
9
50
.1
1.
00
11
4
55
.6
1.
00
0.
12
Ev
er
72
4
46
.3
36
8
49
.9
1.
12
0.
92
1.
36
91
44
.4
0.
96
0.
69
1.
32
M
iss
in
g
0
0
0
Sm
ok
in
g 
sta
tu
s
N
ev
er
84
0
53
.7
36
9
50
.1
1.
00
11
4
55
.6
1.
00
0.
17
Fo
rm
er
39
8
25
.4
20
0
27
.1
1.
11
0.
88
1.
40
50
24
.4
1.
09
0.
74
1.
61
Cu
rre
nt
32
6
20
.8
16
8
22
.8
1.
10
0.
86
1.
41
41
20
0.
82
0.
54
1.
24
M
iss
in
g
0
0
0
Sm
ok
in
g 
do
se
 (p
ack
s p
er 
da
y)
N
ev
er
84
0
53
.8
36
9
50
.1
1.
00
11
4
55
.6
1.
00
0.
02
<
 1
/2
26
5
16
.9
12
1
16
.4
1.
10
0.
84
1.
44
35
17
.1
1.
05
0.
68
1.
63
1/
2 
to
 1
24
4
15
.6
13
2
17
.9
1.
13
0.
86
1.
47
43
21
.0
1.
22
0.
80
1.
84
>
 1
21
2
13
.6
11
4
15
.5
1.
08
0.
81
1.
44
13
6.
3
0.
47
0.
25
0.
89
M
iss
in
g
3
1
0
D
ur
at
io
n 
(ye
ars
)
N
ev
er
84
0
53
.8
36
9
50
.2
1.
00
11
4
55
.6
1.
00
0.
00
≤1
0
21
9
14
.0
89
12
.1
0.
79
0.
58
1.
06
31
15
.1
0.
91
0.
58
1.
44
11
–2
0
18
6
11
.9
79
10
.7
0.
89
0.
65
1.
23
28
13
.7
1.
01
0.
62
1.
64
>
 2
0
31
5
20
.2
19
8
26
.9
1.
51
1.
19
1.
93
32
15
.6
0.
90
0.
57
1.
43
M
iss
in
g
4
2
0
D
ur
at
io
n 
am
on
g 
cu
rre
nt
 (y
ear
s)
N
ev
er
84
0
72
.2
36
9
69
.0
1.
00
11
4
73
.5
1.
00
0.
06
≤1
0
36
3.
1
18
3.
4
0.
68
0.
35
1.
32
5
3.
2
0.
52
0.
19
1.
42
11
–2
0
80
6.
9
26
4.
9
0.
56
0.
34
0.
94
13
8.
4
0.
72
0.
36
1.
45
>
 2
0
20
8
17
.9
12
2
22
.8
1.
41
1.
06
1.
88
23
14
.8
0.
94
0.
56
1.
59
Cancer Causes Control. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Butler et al. Page 18
C
ha
ra
ct
er
ist
ic
s
C
on
tr
o
ls
Lu
m
in
al
Ba
sa
l-l
ik
e
LR
T
C
on
tr
o
ls
C
as
es
O
R
95
 %
 C
I
C
as
es
O
R
95
 %
 C
I
p 
v
a
lu
e
n
%
n
%
n
%
M
iss
in
g
2
2
2
D
ur
at
io
n 
am
on
g 
fo
rm
er
 (y
ear
s)
N
ev
er
84
0
68
.0
36
9
64
.9
1.
00
11
4
69
.5
1.
00
0.
14
≤1
0
18
3
14
.8
71
12
.5
0.
80
0.
58
1.
11
26
15
.9
1.
06
0.
65
1.
73
11
–2
0
10
6
8.
6
53
9.
3
1.
14
0.
78
1.
67
15
9.
1
1.
27
0.
69
2.
34
>
 2
0
10
7
8.
7
76
13
.4
1.
69
1.
18
2.
43
9
5.
5
0.
78
0.
34
1.
80
M
iss
in
g
2
0
0
Ye
ar
s 
sin
ce
 q
ui
tti
ng
 (f
orm
er)
N
ev
er
84
0
67
.9
36
9
65
.1
1.
00
11
4
69
.5
1.
00
0.
91
<
 5
66
5.
3
32
5.
6
0.
89
0.
55
1.
44
9
5.
5
0.
87
0.
39
1.
93
5–
10
78
6.
3
48
8.
5
1.
33
0.
88
2.
01
11
6.
7
1.
25
0.
62
2.
51
11
–2
0
12
6
10
.2
62
10
.9
1.
08
0.
76
1.
54
20
12
.2
1.
25
0.
72
2.
17
>
 2
0
12
7
10
.3
56
9.
9
1.
05
0.
73
1.
51
10
6.
1
0.
85
0.
41
1.
79
M
iss
in
g
1
2
0
A
ge
 at
 in
iti
at
io
n 
(ye
ars
)
N
ev
er
84
0
53
.7
36
9
50
.1
1.
00
11
4
55
.6
1.
00
0.
32
≤1
5
11
2
7.
2
51
6.
9
0.
82
0.
56
1.
21
15
7.
3
0.
89
0.
48
1.
66
16
–2
0
41
0
26
.2
21
3
28
.9
1.
15
0.
91
1.
44
49
23
.9
0.
91
0.
62
1.
34
>
 2
0
20
2
12
.9
10
4
14
.1
1.
18
0.
88
1.
57
27
13
.2
1.
07
0.
66
1.
75
M
iss
in
g
0
0
0
In
iti
at
io
n 
of
 sm
ok
in
g 
re
la
tiv
e 
to
 m
en
ar
ch
e a
nd
 fi
rs
t f
ul
l-t
er
m
 p
re
gn
an
cy
N
ev
er
73
5
52
.8
8
30
9
50
.0
1.
00
10
1
55
.8
1.
00
0.
25
≤M
en
ar
ch
e
43
3.
09
17
2.
8
0.
83
0.
46
1.
53
7
3.
9
1.
18
0.
49
2.
85
A
fte
r m
en
ar
ch
e,
 1
1+
 y
ea
rs
 b
ef
or
e 
FF
TP
63
4.
53
34
5.
5
1.
05
0.
64
1.
73
6
3.
3
0.
78
0.
31
1.
98
A
fte
r m
en
ar
ch
e,
 <
11
 y
ea
rs
 b
ef
or
e 
FF
TP
54
9
39
.5
0
25
8
41
.7
1.
05
0.
84
1.
32
67
37
.0
0.
84
0.
58
1.
22
O
dd
s r
at
io
s f
or
 sm
ok
in
g 
an
d 
br
ea
st 
ca
nc
er
 a
m
on
g 
ca
se
s a
nd
 c
on
tro
ls
O
Rs
 a
dju
ste
d f
or 
ag
e, 
rac
e, 
fam
ily
 h
ist
or
y,
 
al
co
ho
l u
se
, m
en
op
au
sa
l s
ta
tu
s, 
or
al
 c
on
tra
ce
pt
iv
e 
u
se
, 
pa
rit
y,
 
ag
e 
at
 fi
rs
t b
irt
h,
 a
ge
 a
t f
irs
t b
re
as
tfe
ed
in
g,
 a
ge
 a
t m
en
ar
ch
e,
 b
od
y 
m
as
s i
nd
ex
, 
an
d 
of
fs
et
s
LR
T 
lik
el
ih
oo
d 
ra
tio
 te
st
Cancer Causes Control. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Butler et al. Page 19
Ta
bl
e 
4
CB
CS
 I 
an
d 
II
C
ha
ra
ct
er
ist
ic
s
C
on
tr
o
ls
Lu
m
in
al
Ba
sa
l-l
ik
e
LR
T
C
on
tr
o
ls
C
as
es
O
R
95
 %
 C
I
C
as
es
O
R
95
 %
 C
I
p 
v
a
lu
e
n
%
n
%
n
%
B
la
ck
 st
ud
y 
pa
rti
ci
pa
nt
s: 
od
ds
 ra
tio
s f
or
 sm
ok
in
g 
an
d 
Lu
m
in
al
 o
r B
as
al
-li
ke
 b
re
as
t c
an
ce
r r
isk
Sm
ok
in
g 
hi
sto
ry
N
ev
er
42
5
59
.2
15
1
52
.8
1.
00
65
55
.1
1.
00
0.
42
Ev
er
29
3
40
.8
13
5
47
.2
1.
40
1.
03
1.
92
53
44
.9
1.
19
0.
77
1.
83
M
iss
in
g
0
Sm
ok
in
g 
sta
tu
s
N
ev
er
42
5
59
.2
15
1
52
.8
1.
00
65
55
.1
1.
00
0.
02
Fo
rm
er
14
6
20
.3
62
21
.7
1.
20
0.
81
1.
78
32
27
.1
1.
71
1.
02
2.
86
Cu
rre
nt
14
7
20
.5
73
25
.5
1.
53
1.
04
2.
26
21
17
.8
0.
77
0.
43
1.
39
M
iss
in
g
0
0
0
Sm
ok
in
g 
do
se
 (p
ack
s p
er 
da
y)
N
ev
er
42
5
59
.3
15
1
52
.8
1.
00
65
55
.1
1.
00
0.
41
<
 1
/2
13
7
19
.1
57
19
.9
1.
35
0.
90
2.
00
23
19
.5
1.
21
0.
69
2.
10
1/
2–
1
10
5
14
.6
56
19
.6
1.
46
0.
96
2.
22
25
21
.2
1.
36
0.
78
2.
38
>
 1
50
7.
0
22
7.
7
1.
22
0.
68
2.
20
5
4.
2
0.
66
0.
24
1.
78
M
iss
in
g
1
0
0
D
ur
at
io
n 
(ye
ars
)
N
ev
er
42
5
59
.4
15
1
52
.8
1.
00
65
55
.1
1.
00
0.
06
≤1
0
92
12
.8
33
12
.6
0.
97
0.
60
1.
57
17
14
.4
1.
09
0.
59
2.
02
11
–2
0
82
11
.5
27
9.
3
1.
01
0.
60
1.
71
18
15
.3
1.
31
0.
69
2.
47
>
 2
0
11
7
16
.3
75
25
.2
2.
06
1.
38
3.
06
18
15
.3
1.
13
0.
61
2.
10
M
iss
in
g
2
0
0
W
hi
te
 st
ud
y 
pa
rti
ci
pa
nt
s: 
od
ds
 ra
tio
s f
or
 sm
ok
in
g 
an
d 
Lu
m
in
al
 o
r B
as
al
-li
ke
 b
re
as
t c
an
ce
r r
isk
Sm
ok
in
g 
hi
sto
ry
N
ev
er
41
5
49
.1
21
8
48
.3
1.
00
49
56
.3
1.
00
0.
30
Ev
er
43
1
50
.9
23
3
51
.7
0.
99
0.
77
1.
28
38
43
.7
0.
76
0.
46
1.
25
Cancer Causes Control. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Butler et al. Page 20
C
ha
ra
ct
er
ist
ic
s
C
on
tr
o
ls
Lu
m
in
al
Ba
sa
l-l
ik
e
LR
T
C
on
tr
o
ls
C
as
es
O
R
95
 %
 C
I
C
as
es
O
R
95
 %
 C
I
p 
v
a
lu
e
n
%
n
%
n
%
M
iss
in
g
0
0
0
Sm
ok
in
g 
sta
tu
s
N
ev
er
41
5
49
.1
21
8
48
.3
1.
00
49
56
.3
1.
00
0.
31
Fo
rm
er
25
2
29
.8
13
8
30
.6
1.
05
0.
78
1.
40
18
20
.7
0.
68
0.
36
1.
27
Cu
rre
nt
17
9
21
.2
95
21
.1
0.
91
0.
65
1.
26
20
23
.0
0.
86
0.
47
1.
60
M
iss
in
g
0
0
0
Sm
ok
in
g 
do
se
 (p
ack
s p
er 
da
y)
N
ev
er
41
5
49
.2
21
8
48
.4
1.
00
49
56
.3
1.
00
0.
10
<
 1
/2
12
8
15
.2
64
14
.2
0.
95
0.
66
1.
37
12
13
.8
1.
01
0.
48
2.
10
1/
2–
1
13
9
16
.5
76
16
.9
0.
97
0.
69
1.
38
18
20
.7
1.
05
0.
55
1.
98
>
 1
16
2
19
.2
92
20
.4
1.
03
0.
73
1.
43
8
9.
2
0.
38
0.
16
0.
90
M
iss
in
g
2
1
0
D
ur
at
io
n 
(ye
ars
)
N
ev
er
41
5
49
.2
21
8
49
.2
1.
00
49
56
.3
1.
00
0.
14
≤1
0
12
7
15
.0
56
11
.6
0.
70
0.
47
1.
02
14
16
.1
0.
78
0.
39
1.
56
11
–2
0
10
4
12
.3
52
11
.4
0.
84
0.
56
1.
25
10
11
.5
0.
66
0.
30
1.
44
>
 2
0
19
8
23
.5
12
3
27
.8
1.
31
0.
96
1.
79
14
16
.1
0.
79
0.
39
1.
59
M
iss
in
g
2
2
0
O
Rs
 a
dju
ste
d f
or 
ag
e, 
fam
ily
 h
ist
or
y,
 
al
co
ho
l u
se
, m
en
op
au
sa
l s
ta
tu
s, 
or
al
 c
on
tra
ce
pt
iv
e 
u
se
, 
pa
rit
y,
 
ag
e 
at
 fi
rs
t b
irt
h,
 a
ge
 a
t f
irs
t b
re
as
tfe
ed
in
g,
 a
ge
 a
t m
en
ar
ch
e,
 b
od
y 
m
as
s i
nd
ex
, 
an
d 
of
fs
et
s
LR
T 
lik
el
ih
oo
d 
ra
tio
 te
st
Cancer Causes Control. Author manuscript; available in PMC 2017 June 01.
